AU Patent

AU2024266870A1 — Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions

Assigned to Tonix Pharma Holdings Ltd · Expires 2024-12-12 · 1y expired

What this patent protects

Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of 5 agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.

USPTO Abstract

Compositions comprising cyclobenzaprine, and methods for the treatment or prevention of 5 agitation, psychosis and/or cognitive decline and associated symptoms thereof in dementia and other neurodegenerative conditions.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024266870A1
Jurisdiction
AU
Classification
—
Expires
2024-12-12
Drug substance claim
No
Drug product claim
No
Assignee
Tonix Pharma Holdings Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.